跳到正文
原文
MedPage Today·· 11 天前精选AI 评分75

为什么不用西罗莫司治疗活动性狼疮?

Why Not Sirolimus for Active Lupus?

AI 导读

一项来自中国的随机对照试验显示,西罗莫司作为二线治疗对活动性系统性红斑狼疮(SLE)患者有效,54.3%的患者在24周内达到临床显著改善,但安全性问题仍需关注。

推荐理由

研究显示西罗莫司作为二线治疗对SLE有效,但安全性问题仍需关注。

正文

— Trial shows sirolimus very effective as second-line treatment, but safety issues simmer

by John Gever, Contributing Writer, MedPage Today

November 9, 2026 • 3 min read

ORLANDO -- Patients with systemic lupus erythematosus (SLE) that is uncontrolled despite standard therapy did well with a daily oral dose of sirolimus in a trial from China, although safety concerns weren't entirely relieved.

In a 145-patient randomized trial, 54.3% of those assigned to 1.5 mg/day of the ultrapotent immunosuppressant achieved so-called SRI-4 responses within 24 weeks, indicating clinically significant improvement, compared with 22.7% of patients receiving placebo (difference 31.6 percentage points, 95% CI 16.6-46.7), according to Liying Peng, MD, of Peking Union Medical Hospital in Beijing.

Secondary endpoints all favored sirolimus, including changes in SLE Disease Activity Index 2000 (SLEDAI-2K) score and achievement of low lupus disease activity state (LLDAS), she told attendees at the American College of Rheumatology's annual meeting.

Of course, safety is a major concern with sirolimus, insofar as the drug inhibits a broad range of immune activity and thus brings substantial risk for infections. But if these 24-week data can be relied on, the risks may prove to be acceptable for patients in need of an easily accessed therapy for refractory SLE. Of the 70 patients receiving the drug, only two serious infections were recorded, and just four stopped sirolimus because of adverse events, Peng said. One patient in each arm died, but these were considered unrelated to treatment. The most frequent adverse clinical event was menstrual irregularity (14%, versus none in the placebo group).

Adverse effects were common with sirolimus but were primarily laboratory abnormalities. These included a 50% rate of elevated triglycerides, 37% for increased cholesterol, and 27% and 21% for leukopenia and neutropenia, respectively. If the trial had continued for longer, it's likely that related clinical problems would have arisen; an ongoing 24-week, open-label extension phase should shed more light. But Peng made no suggestion that, in ordinary clinical use, sirolimus would need to be continued indefinitely for patients who respond adequately.

Peng's is not the first study to examine sirolimus as a lupus treatment. A Lancet report in 2018 described the immunosuppressant's use in 43 patients with refractory SLE, yielding a 50% reduction in SLEDAI-2K scores without major safety issues among the 29 who completed a full year of therapy. That was a single-arm, unblinded trial, however, prompting Peng and colleagues to mount the current double-blind, placebo-controlled trial.

To be eligible, patients needed a SLEDAI-2K score of at least 4 after having received standard antimalarials or immunosuppressants such as mycophenolate mofetil for 12 weeks or longer. Those with substantial renal impairment, other comorbid autoimmune conditions, or a recent history of more potent immunosuppressive therapy (intravenous cyclophosphamide, for example) were excluded. All patients continued on standard medications during the trial.

Mean age of the trial participants was about 35, and over 90% were women. Disease duration averaged some 9 years. Baseline SLEDAI-2K scores stood at roughly 10, and Physician Global Assessment (PGA) scores averaged just over 1.4. About 40% showed moderate renal involvement.

SRI-4 served as the primary outcome. It combines three separate endpoints: at least 4-point reduction in SLEDAI-2K score, at least 0.3-point improvement in PGA score, and no more than one organ with new moderate involvement plus no new serious involvement. Secondary endpoints, in addition to those noted above, included clinical response by British Isles Composite Lupus Assessment (BICLA) criteria, achievement of SLEDAI-2K of zero ("clinical remission"), and change from baseline in PGA score.

BICLA responses were achieved by 60% as opposed to 31% with placebo at 24 weeks. SLEDAI-2K fell by an average 4.7 points with sirolimus versus 1.0 point with placebo. Biomarkers such as anti-double stranded DNA antibody titers all improved markedly.

More stringent outcomes, however, were difficult to achieve. Only 14% of the sirolimus group got to full clinical remission, and 24% to LLDAS, which is similar to SRI-4 but stricter, with no activity in major organs.

Overall, the outcomes with sirolimus were similar to those typically seen with biologic drugs for lupus. But as Peng explained, "cost and access remain barriers" to their use. This is not just an issue for less developed nations -- while biologics such as belimumab (Benlysta) are usually covered under Medicaid in the U.S., prior authorization and quantity limits apply in many states. As a shelf-stable oral tablet, sirolimus may also be more practical for certain patients.

来源:MedPage Today · medpagetoday.com